155 related articles for article (PubMed ID: 9834102)
61. Flt3 ligand enhances anti-tumor effects of antibody therapeutics.
Maruyama K; Selmani Z; Ishii H; Tai S; Cheng J; Akimoto S; Watanabe M; Yamaguchi K
Int Immunopharmacol; 2012 Mar; 12(3):481-6. PubMed ID: 22245429
[TBL] [Abstract][Full Text] [Related]
62. Characterization of the antitumor activity of a polyantigenic immunomodulator (PAI): II--Involvement of NK cells and adoptive immunotherapy.
Orraca ZM; Ríos-Olivares E; Carrasco-Canales JA; Aquino E; Marchand AM; Colón JI
Bol Asoc Med P R; 1989 Jul; 81(7):254-8. PubMed ID: 2775402
[TBL] [Abstract][Full Text] [Related]
63. Antitumor effects of Flt3 ligand in transplanted murine tumor models.
Averbook BJ; Schuh JL; Papay R; Maliszewski C
J Immunother; 2002; 25(1):27-35. PubMed ID: 11924908
[TBL] [Abstract][Full Text] [Related]
64. Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma.
Zeis M; Zunkel T; Steinmann J; Schmitz N; Uharek L
Br J Haematol; 2002 Apr; 117(1):93-102. PubMed ID: 11918538
[TBL] [Abstract][Full Text] [Related]
65. Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver.
Bayón LG; Izquierdo MA; Sirovich I; van Rooijen N; Beelen RH; Meijer S
Hepatology; 1996 May; 23(5):1224-31. PubMed ID: 8621157
[TBL] [Abstract][Full Text] [Related]
66. Treatment of hepatocellular carcinoma with adeno-associated virus encoding interleukin-15 superagonist.
Chang CM; Lo CH; Shih YM; Chen Y; Wu PY; Tsuneyama K; Roffler SR; Tao MH
Hum Gene Ther; 2010 May; 21(5):611-21. PubMed ID: 20064014
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of the antitumor activity of interleukin-12 in an experimental murine model of colorectal cancer induced by 1,2 dimethyl-hydrazine (DMH).
Coca S; Enrech S; Moreno García V; Sáez MA; Gutiérrez C; Colmenarejo A; Hernández JM; Pérez Piqueras J
Rev Esp Enferm Dig; 2005 Sep; 97(9):619-28. PubMed ID: 16266234
[TBL] [Abstract][Full Text] [Related]
68. Intensified regression of colon cancer liver metastases in mice treated with irinotecan and the immunomodulator JBT 3002.
Shinohara H; Bucana CD; Killion JJ; Fidler IJ
J Immunother; 2000; 23(3):321-31. PubMed ID: 10838661
[TBL] [Abstract][Full Text] [Related]
69. Dendritic cells in models of tumor immunity. Role of Flt3 ligand.
Maliszewski C
Pathol Biol (Paris); 2001 Jul; 49(6):481-3. PubMed ID: 11484609
[TBL] [Abstract][Full Text] [Related]
70. T-lymphocytes and macrophages in primary murine fibrosarcomas at different stages in their progression.
Wood GW; Gollahon KA
Cancer Res; 1978 Jul; 38(7):1857-65. PubMed ID: 350380
[TBL] [Abstract][Full Text] [Related]
71. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.
Morse MA; Nair S; Fernandez-Casal M; Deng Y; St Peter M; Williams R; Hobeika A; Mosca P; Clay T; Cumming RI; Fisher E; Clavien P; Proia AD; Niedzwiecki D; Caron D; Lyerly HK
J Clin Oncol; 2000 Dec; 18(23):3883-93. PubMed ID: 11099317
[TBL] [Abstract][Full Text] [Related]
72. [Detection of the cytotoxic effect of tumor cells against the targets of normal killers].
Fuks BB; Zedginidze MS; Spirande IV; Kogarko IN; Sterlina AG
Biull Eksp Biol Med; 1981 Sep; 92(9):342-5. PubMed ID: 7295991
[TBL] [Abstract][Full Text] [Related]
73. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.
Yang H; Brackett CM; Morales-Tirado VM; Li Z; Zhang Q; Wilson MW; Benjamin C; Harris W; Waller EK; Gudkov AV; Burdelya LG; Grossniklaus HE
Oncotarget; 2016 Jan; 7(3):2936-50. PubMed ID: 26655090
[TBL] [Abstract][Full Text] [Related]
74. Differential regulation of epidermal and dermal dendritic cells by IL-12 and Flt3 ligand.
Esche C; Subbotin VM; Hunter O; Peron JM; Maliszewski C; Lotze MT; Shurin MR
J Invest Dermatol; 1999 Dec; 113(6):1028-32. PubMed ID: 10594747
[TBL] [Abstract][Full Text] [Related]
75. Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo.
Lynch DH
Crit Rev Immunol; 1998; 18(1-2):99-107. PubMed ID: 9419452
[TBL] [Abstract][Full Text] [Related]
76. Flt3 ligand treatment reverses endotoxin tolerance-related immunoparalysis.
Wysocka M; Montaner LJ; Karp CL
J Immunol; 2005 Jun; 174(11):7398-402. PubMed ID: 15905588
[TBL] [Abstract][Full Text] [Related]
77. Abdominal Infection Suppresses the Number and Activity of Intrahepatic Natural Killer Cells and Promotes Tumor Growth in a Murine Liver Metastasis Model.
Matsumoto Y; Tsujimoto H; Ono S; Shinomiya N; Miyazaki H; Hiraki S; Takahata R; Yoshida K; Saitoh D; Yamori T; Yamamoto J; Hase K
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S257-65. PubMed ID: 25752891
[TBL] [Abstract][Full Text] [Related]
78. Significant reduction of laparotomy-associated lung metastases and subcutaneous tumors after perioperative immunomodulation with flt3 ligand in mice.
Carter JJ; Feingold DL; Wildbrett P; Oh A; Kirman I; Asi Z; Stapleton G; Huang E; Fine RL; Whelan RL
Surg Innov; 2005 Dec; 12(4):319-25. PubMed ID: 16424952
[TBL] [Abstract][Full Text] [Related]
79. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
80. Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.
Ryschich E; Huszty G; Wentzensen N; Schmidt E; Knaebel HP; Encke J; Märten A; Büchler MW; Schmidt J
Int J Colorectal Dis; 2007 Feb; 22(2):215-23. PubMed ID: 16528542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
